Longwood Fund was founded in 2010 by Christoph Westphal, Michelle Dipp and Richard Aldrich. Longwood Fund Management, LLC operates as a venture capital firm. The company invests in healthcare and life science sectors with a focus on biotechnology and therapeutics. Longwood Fund Management serves its clients in the United States.
Longwood's mission is to identify technologies and fund companies that make a difference in the lives of patients, and also create significant value for investors. Longwood's stated goal is to launch and building healthcare companies and provide operational leadership and strategic guidance.
Christoph Westphal MD, PhD, has served as co-founder, CEO, and lead investor of six companies (including Alnylam, Acceleron, Sirtris, and Momenta) that have completed IPOs, yielding an aggregate, sustained, value of $16 billion. Rich Aldrich was a co-founder of Vertex Pharmaceuticals, which currently has a market capitalisation of $60 billion.
Longwood Founders Fund invests during early stage and late stage venture as well as dealing with Private Equity. Longwood Founders Fund has raised a total of $85 million across 4 funds, their latest being Longwood Fund V. Investments include Recros Medica, Bicycle Therapeutics and Channel Medsystems with exits including Flex Pharma, Verastem Oncology and PTC Therapeutics.